Nasdaq CopenhagenIFRS · DKK

NORDIC BIOSCIENCE HOLDING A/S

NORDIC BIOSCIENCE HOLDING A/S is a Danish holding company with consolidated accounts, headquartered in Hellerup, Denmark. The available filing excerpt does not disclose the operating business of the group, so the company can only be identified here as a corporate holding structure rather than a specific operating product company.

Liikevaihto426milj. DKK
−19,2 %v/v
Nettotulos54,5milj. DKK
−68,1 %v/v
Vapaa kassavirta−68,6milj. DKK
−118,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2023–2025

−2000200400600milj. DKK2023: 190 milj. DKK2023: EBIT −18 milj. DKK20232024: 527 milj. DKK2024: EBIT 198 milj. DKK20242025: 426 milj. DKK2025426
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Holding company services100 %

Corporate ownership, governance, and oversight of consolidated subsidiaries.

Asiakkaat

The available information does not identify external customer segments or end markets for the group. As a holding company, its value is likely derived from ownership and oversight of subsidiaries rather than direct sales to customers.

Subsidiary investments

The holding company’s economic exposure is to its controlled group companies and their underlying businesses.

Maantiede

The company is based in Denmark, with its registered address in Hellerup. No revenue geography, operating country, or international market breakdown is disclosed in the provided material, so the business footprint cannot be reliably mapped beyond the Danish parent entity.

Riskit

The main identifiable risk is information risk: the provided material does not disclose the operating business, revenue base, or customer exposure of the group. As a holding structure, the company would also be exposed to subsidiary performance, valuation uncertainty, and dependence on the value of its investments, but the excerpt does not provide enough detail to quantify those risks.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Subsidiary valuation and impairment1Undisclosed operating business2
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Subsidiary valuation and impairmentVaikutus: KorkeaTodennäköisyys: Kohtalainen

    A holding company depends on the carrying value of investments, which can be sensitive to underlying performance and fair value assumptions.

    Kohdistuu: Investment portfolio

  2. Undisclosed operating businessVaikutus: KeskitasoTodennäköisyys: Korkea

    The filing excerpt does not identify what the group actually sells or where it operates, limiting investor visibility.

    Kohdistuu: Corporate disclosure quality

Kirjanpito

Harkinnanvaraiset erät
Consolidation accounting

Reported results depend on which subsidiaries are consolidated and how intra-group balances are eliminated.

Vaikutus: Affects balance sheet and group-level equity

Investment impairment

Holding companies often carry investments at cost or fair value, requiring judgment on recoverability.

Vaikutus: Can materially affect profit and equity

Foreign currency translation

The filing references reserves of exchange differences on translation, which can affect equity volatility.

Vaikutus: Impacts other comprehensive income and equity

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.10.2026